Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

V. Beral; C. Hermon; R. Peto; G. Reeves; L. Brinton; P. Marchbanks; E. Negri; R. Ness; P. H. M. Peeters; M. Vessey; E. E. Calle; S. M. Gapstur; A. V. Patel; L. Dal Maso; R. Talamini; A. Chetrit; G. Hirsh-Yechezkel; F. Lubin; S. Sadetzki; N. Allen; D. Bull; K. Callaghan; B. Crossley; K. Gaitskell; A. Goodill; J. Green; T. Key; K. Moser; R. Collins; R. Doll; C. A. Gonzalez; N. Lee; H. W. Ory; H. B. Peterson; P. A. Wingo; N. Martin; T. Pardthaisong; S. Silpisornkosol; C. Theetranont; B. Boosiri; S. Chutivongse; P. Jimakorn; P. Virutamasen; C. Wongsrichanalai; A. Tjonneland; L. Titus-Ernstoff; T. Byers; T. Rohan; B. J. Mosgaard; D. Yeates; J. L. Freudenheim; J. Chang-Claude; R. Kaaks; K. E. Anderson; A. Folsom; K. Robien; M. A. Rossing; D. B. Thomas; N. S. Weiss; E. Riboli; F. Clavel-Chapelon; D. Cramer; S. E. Hankinson; S. S. Tworoger; S. Franceschi; C. La Vecchia; C. Magnusson; T. Riman; E. Weiderpass; A. Wolk; L. J. Schouten; P. A. van den Brandt; N. Chantarakul; S. Koetsawang; D. Rachawat; D. Palli; A. Black; A. Berrington de Gonzalez; D. M. Freedman; P. Hartge; A. W. Hsing; J. V. Lacey Jr; R. N. Hoover; C. Schairer; S. Graff-Iversen; R. Selmer; C. J. Bain; A. C. Green; D. M. Purdie; V. Siskind; P. M. Webb; S. E. McCann; P. Hannaford; C. Kay; C. W. Binns; A. H. Lee; M. Zhang; R. B. Ness; P. Nasca; P. F. Coogan; J. R. Palmer; L. Rosenberg; J. Kelsey; R. Paffenbarger; A. Whittemore; K. Katsouyanni; A. Trichopoulou; D. Trichopoulos; A. Tzonou; A. Dabancens; L. Martinez; R. Molina; O. Salas; M. T. Goodman; G. Lurie; M. E. Carney; L. R. Wilkens; Linda Werner Hartman; Jonas Manjer; Håkan Olsson; J. A. Grisso; M. Morgan; J. E. Wheeler; J. Casagrande; M. C. Pike; R. K. Ross; A. H. Wu; A. B. Miller; M. Kumle; E. Lund; L. McGowan; X. O. Shu; W. Zheng; T. M. M. Farley; S. Holck; O. Meirik; H. A. Risch

doi:10.1371/journal.pmed.1001200

Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

V. Beral, C. Hermon, R. Peto, G. Reeves, L. Brinton, P. Marchbanks, E. Negri, R. Ness, P. H. M. Peeters, M. Vessey, E. E. Calle, S. M. Gapstur, A. V. Patel, L. Dal Maso, R. Talamini, A. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki, N. AllenD. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, T. Key, K. Moser, R. Collins, R. Doll, C. A. Gonzalez, N. Lee, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland, L. Titus-Ernstoff, T. Byers, T. Rohan, B. J. Mosgaard, D. Yeates, J. L. Freudenheim, J. Chang-Claude, R. Kaaks, K. E. Anderson, A. Folsom, K. Robien, M. A. Rossing, D. B. Thomas, N. S. Weiss, E. Riboli, F. Clavel-Chapelon, D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, C. Magnusson, T. Riman, E. Weiderpass, A. Wolk, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, A. Berrington de Gonzalez, D. M. Freedman, P. Hartge, A. W. Hsing, J. V. Lacey Jr, R. N. Hoover, C. Schairer, S. Graff-Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, S. E. McCann, P. Hannaford, C. Kay, C. W. Binns, A. H. Lee, M. Zhang, R. B. Ness, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou, A. Dabancens, L. Martinez, R. Molina, O. Salas, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilkens, Linda Werner Hartman, Jonas Manjer, Håkan Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, J. Casagrande, M. C. Pike, R. K. Ross, A. H. Wu, A. B. Miller, M. Kumle, E. Lund, L. McGowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, H. A. Risch

Research output: Contribution to journal › Article › peer-review

238 Downloads (Pure)

Abstract

Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.

Original language	English
Journal	PLoS Medicine
Volume	9
Issue number	4
DOIs	https://doi.org/10.1371/journal.pmed.1001200
Publication status	Published - 2012

Subject classification (UKÄ)

Surgery
Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pmed.1001200

Plos_Beral_et_al

Cite this

Beral, V., Hermon, C., Peto, R., Reeves, G., Brinton, L., Marchbanks, P., Negri, E., Ness, R., Peeters, P. H. M., Vessey, M., Calle, E. E., Gapstur, S. M., Patel, A. V., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., ... Risch, H. A. (2012). Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies. PLoS Medicine, 9(4). https://doi.org/10.1371/journal.pmed.1001200

@article{cb3ca67a2b8c42a38f5b41d963f977dc,

title = "Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies",

abstract = "Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.",

author = "V. Beral and C. Hermon and R. Peto and G. Reeves and L. Brinton and P. Marchbanks and E. Negri and R. Ness and Peeters, {P. H. M.} and M. Vessey and Calle, {E. E.} and Gapstur, {S. M.} and Patel, {A. V.} and {Dal Maso}, L. and R. Talamini and A. Chetrit and G. Hirsh-Yechezkel and F. Lubin and S. Sadetzki and N. Allen and D. Bull and K. Callaghan and B. Crossley and K. Gaitskell and A. Goodill and J. Green and T. Key and K. Moser and R. Collins and R. Doll and Gonzalez, {C. A.} and N. Lee and Ory, {H. W.} and Peterson, {H. B.} and Wingo, {P. A.} and N. Martin and T. Pardthaisong and S. Silpisornkosol and C. Theetranont and B. Boosiri and S. Chutivongse and P. Jimakorn and P. Virutamasen and C. Wongsrichanalai and A. Tjonneland and L. Titus-Ernstoff and T. Byers and T. Rohan and Mosgaard, {B. J.} and D. Yeates and Freudenheim, {J. L.} and J. Chang-Claude and R. Kaaks and Anderson, {K. E.} and A. Folsom and K. Robien and Rossing, {M. A.} and Thomas, {D. B.} and Weiss, {N. S.} and E. Riboli and F. Clavel-Chapelon and D. Cramer and Hankinson, {S. E.} and Tworoger, {S. S.} and S. Franceschi and {La Vecchia}, C. and C. Magnusson and T. Riman and E. Weiderpass and A. Wolk and Schouten, {L. J.} and {van den Brandt}, {P. A.} and N. Chantarakul and S. Koetsawang and D. Rachawat and D. Palli and A. Black and {de Gonzalez}, {A. Berrington} and Freedman, {D. M.} and P. Hartge and Hsing, {A. W.} and {Lacey Jr}, {J. V.} and Hoover, {R. N.} and C. Schairer and S. Graff-Iversen and R. Selmer and Bain, {C. J.} and Green, {A. C.} and Purdie, {D. M.} and V. Siskind and Webb, {P. M.} and McCann, {S. E.} and P. Hannaford and C. Kay and Binns, {C. W.} and Lee, {A. H.} and M. Zhang and Ness, {R. B.} and P. Nasca and Coogan, {P. F.} and Palmer, {J. R.} and L. Rosenberg and J. Kelsey and R. Paffenbarger and A. Whittemore and K. Katsouyanni and A. Trichopoulou and D. Trichopoulos and A. Tzonou and A. Dabancens and L. Martinez and R. Molina and O. Salas and Goodman, {M. T.} and G. Lurie and Carney, {M. E.} and Wilkens, {L. R.} and {Werner Hartman}, Linda and Jonas Manjer and H{\aa}kan Olsson and Grisso, {J. A.} and M. Morgan and Wheeler, {J. E.} and J. Casagrande and Pike, {M. C.} and Ross, {R. K.} and Wu, {A. H.} and Miller, {A. B.} and M. Kumle and E. Lund and L. McGowan and Shu, {X. O.} and W. Zheng and Farley, {T. M. M.} and S. Holck and O. Meirik and Risch, {H. A.}",

year = "2012",

doi = "10.1371/journal.pmed.1001200",

language = "English",

volume = "9",

journal = "PLoS Medicine",

issn = "1549-1676",

publisher = "Public Library of Science (PLoS)",

number = "4",

}

Beral, V, Hermon, C, Peto, R, Reeves, G, Brinton, L, Marchbanks, P, Negri, E, Ness, R, Peeters, PHM, Vessey, M, Calle, EE, Gapstur, SM, Patel, AV, Dal Maso, L, Talamini, R, Chetrit, A, Hirsh-Yechezkel, G, Lubin, F, Sadetzki, S, Allen, N, Bull, D, Callaghan, K, Crossley, B, Gaitskell, K, Goodill, A, Green, J, Key, T, Moser, K, Collins, R, Doll, R, Gonzalez, CA, Lee, N, Ory, HW, Peterson, HB, Wingo, PA, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Tjonneland, A, Titus-Ernstoff, L, Byers, T, Rohan, T, Mosgaard, BJ, Yeates, D, Freudenheim, JL, Chang-Claude, J, Kaaks, R, Anderson, KE, Folsom, A, Robien, K, Rossing, MA, Thomas, DB, Weiss, NS, Riboli, E, Clavel-Chapelon, F, Cramer, D, Hankinson, SE, Tworoger, SS, Franceschi, S, La Vecchia, C, Magnusson, C, Riman, T, Weiderpass, E, Wolk, A, Schouten, LJ, van den Brandt, PA, Chantarakul, N, Koetsawang, S, Rachawat, D, Palli, D, Black, A, de Gonzalez, AB, Freedman, DM, Hartge, P, Hsing, AW, Lacey Jr, JV, Hoover, RN, Schairer, C, Graff-Iversen, S, Selmer, R, Bain, CJ, Green, AC, Purdie, DM, Siskind, V, Webb, PM, McCann, SE, Hannaford, P, Kay, C, Binns, CW, Lee, AH, Zhang, M, Ness, RB, Nasca, P, Coogan, PF, Palmer, JR, Rosenberg, L, Kelsey, J, Paffenbarger, R, Whittemore, A, Katsouyanni, K, Trichopoulou, A, Trichopoulos, D, Tzonou, A, Dabancens, A, Martinez, L, Molina, R, Salas, O, Goodman, MT, Lurie, G, Carney, ME, Wilkens, LR, Werner Hartman, L , Manjer, J, Olsson, H, Grisso, JA, Morgan, M, Wheeler, JE, Casagrande, J, Pike, MC, Ross, RK, Wu, AH, Miller, AB, Kumle, M, Lund, E, McGowan, L, Shu, XO, Zheng, W, Farley, TMM, Holck, S, Meirik, O & Risch, HA 2012, 'Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies', PLoS Medicine, vol. 9, no. 4. https://doi.org/10.1371/journal.pmed.1001200

TY - JOUR

T1 - Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

AU - Beral, V.

AU - Hermon, C.

AU - Peto, R.

AU - Reeves, G.

AU - Brinton, L.

AU - Marchbanks, P.

AU - Negri, E.

AU - Ness, R.

AU - Peeters, P. H. M.

AU - Vessey, M.

AU - Calle, E. E.

AU - Gapstur, S. M.

AU - Patel, A. V.

AU - Dal Maso, L.

AU - Talamini, R.

AU - Chetrit, A.

AU - Hirsh-Yechezkel, G.

AU - Lubin, F.

AU - Sadetzki, S.

AU - Allen, N.

AU - Bull, D.

AU - Callaghan, K.

AU - Crossley, B.

AU - Gaitskell, K.

AU - Goodill, A.

AU - Green, J.

AU - Key, T.

AU - Moser, K.

AU - Collins, R.

AU - Doll, R.

AU - Gonzalez, C. A.

AU - Lee, N.

AU - Ory, H. W.

AU - Peterson, H. B.

AU - Wingo, P. A.

AU - Martin, N.

AU - Pardthaisong, T.

AU - Silpisornkosol, S.

AU - Theetranont, C.

AU - Boosiri, B.

AU - Chutivongse, S.

AU - Jimakorn, P.

AU - Virutamasen, P.

AU - Wongsrichanalai, C.

AU - Tjonneland, A.

AU - Titus-Ernstoff, L.

AU - Byers, T.

AU - Rohan, T.

AU - Mosgaard, B. J.

AU - Yeates, D.

AU - Freudenheim, J. L.

AU - Chang-Claude, J.

AU - Kaaks, R.

AU - Anderson, K. E.

AU - Folsom, A.

AU - Robien, K.

AU - Rossing, M. A.

AU - Thomas, D. B.

AU - Weiss, N. S.

AU - Riboli, E.

AU - Clavel-Chapelon, F.

AU - Cramer, D.

AU - Hankinson, S. E.

AU - Tworoger, S. S.

AU - Franceschi, S.

AU - La Vecchia, C.

AU - Magnusson, C.

AU - Riman, T.

AU - Weiderpass, E.

AU - Wolk, A.

AU - Schouten, L. J.

AU - van den Brandt, P. A.

AU - Chantarakul, N.

AU - Koetsawang, S.

AU - Rachawat, D.

AU - Palli, D.

AU - Black, A.

AU - de Gonzalez, A. Berrington

AU - Freedman, D. M.

AU - Hartge, P.

AU - Hsing, A. W.

AU - Lacey Jr, J. V.

AU - Hoover, R. N.

AU - Schairer, C.

AU - Graff-Iversen, S.

AU - Selmer, R.

AU - Bain, C. J.

AU - Green, A. C.

AU - Purdie, D. M.

AU - Siskind, V.

AU - Webb, P. M.

AU - McCann, S. E.

AU - Hannaford, P.

AU - Kay, C.

AU - Binns, C. W.

AU - Lee, A. H.

AU - Zhang, M.

AU - Ness, R. B.

AU - Nasca, P.

AU - Coogan, P. F.

AU - Palmer, J. R.

AU - Rosenberg, L.

AU - Kelsey, J.

AU - Paffenbarger, R.

AU - Whittemore, A.

AU - Katsouyanni, K.

AU - Trichopoulou, A.

AU - Trichopoulos, D.

AU - Tzonou, A.

AU - Dabancens, A.

AU - Martinez, L.

AU - Molina, R.

AU - Salas, O.

AU - Goodman, M. T.

AU - Lurie, G.

AU - Carney, M. E.

AU - Wilkens, L. R.

AU - Werner Hartman, Linda

AU - Manjer, Jonas

AU - Olsson, Håkan

AU - Grisso, J. A.

AU - Morgan, M.

AU - Wheeler, J. E.

AU - Casagrande, J.

AU - Pike, M. C.

AU - Ross, R. K.

AU - Wu, A. H.

AU - Miller, A. B.

AU - Kumle, M.

AU - Lund, E.

AU - McGowan, L.

AU - Shu, X. O.

AU - Zheng, W.

AU - Farley, T. M. M.

AU - Holck, S.

AU - Meirik, O.

AU - Risch, H. A.

PY - 2012

Y1 - 2012

N2 - Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.

AB - Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.

U2 - 10.1371/journal.pmed.1001200

DO - 10.1371/journal.pmed.1001200

M3 - Article

SN - 1549-1676

VL - 9

JO - PLoS Medicine

JF - PLoS Medicine

IS - 4

ER -

Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this